Recce Pharmaceuticals’ Australian patent to be granted for RECCE® Anti-Infectives

Recce Pharmaceuticals Limited (ASX: RCE) announced that the Australian Patent Office issued notification of intent to grant Recce’s Patent Family 3 “Anti-Virus Agent and Method for Treatment of Viral Infection”. The company stated that Family 3 would be the final patent, after those already granted in the biggest pharmaceutical markets in the world such as China, Japan, Europe and Hong Kong.

“Receiving notice that this Australian patent application will proceed to grant is another milestone in the Company’s global IP strategy; and are thrilled by the yet further validation to the potential importance of our infectious disease compounds”, Chief Executive Officer, James Graham said.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com